Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose-Escalation Safety Study of Brentuximab Vedotin in Combination With Multi-Agent Chemotherapy as Frontline Therapy in Patients With Hodgkin Lymphoma

NCT01060904 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT01060904
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01060904 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose-Escalation Safety Study of Brentuximab Vedotin in Combination With Multi-Agent Chemotherapy as Frontline Therapy in Patients With Hodgkin Lymphoma
Lead sponsor
Seagen Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2010
Completion date
September 30, 2012
Enrollment
51 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

disease, hodgkin